View Older Stories
-
William Blair stays Outperform on Viking Therapeutic (VKTX) amid 'torrid pace' in advancing VK2735
-
Morgan Stanley on Viking Therapeutics (VKTX): 'encouraged' by execution, patient demand
-
Viking Therapeutics (VKTX) call put ratio 5.6 calls to 1 put with a focus on March 27 weekly calls
-
Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this year"
-
Truist on Viking Therapeutic (VKTX): 'Riding High On A Winning (GLP+GIP) Combination As Commercial Strategy Takes Shape'
-
Viking Therapeutic (VKTX) PT Lowered to $118 at Raymond James
-
Laidlaw Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) Misses Q4 EPS by 48c
-
Viking Therapeutics (VKTX) call put ratio 2.8 calls to 1 put as share price up 17.2%
-
Viking Therapeutics completes enrollment in VK2735 maintenance trial
-
Viking Therapeutics (VKTX) call put ratio 5.2 calls to 1 put with a focus on December 5 weekly calls
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutic (VKTX) PT Raised to $107 at Canaccord Genuity
-
Viking Therapeutics presents VK2735 obesity data at ObesityWeek 2025
-
Canaccord Genuity Starts Viking Therapeutic (VKTX) at Buy
-
Viking Therapeutics (VKTX) call put ratio 5.4 calls to 1 put with a focus on January 50 calls as share price up 9%
-
Viking Therapeutic (VKTX) PT Raised to $105 at Cantor Fitzgerald
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
BTIG Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) Misses Q3 EPS by 11c
-
Viking Therapeutics begins VK2735 maintenance dosing trial for obesity
-
Viking Therapeutics (VKTX) call put ratio 7.8 calls to 1 put with a focus on January 45 calls
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) call put ratio 5 calls to 1 put with a focus on November 25 and 37.50 calls
-
Novo Nordisk (NVO) stock: Barclays breaks down key investor questions and debates
-
Mizuho Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Raymond James Reiterates Strong Buy Rating on Viking Therapeutic (VKTX)
-
Laidlaw Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) call put ratio 2.8 calls to 1 put with a focus on August 22 weekly calls
-
Raymond James Reiterates Strong Buy Rating on Viking Therapeutic (VKTX), PT $122
-
Morgan Stanley Reiterates Overweight Rating on Viking Therapeutic (VKTX)
-
Jefferies on Viking Therapeutic (VKTX): 'We think the market is overreacting'
-
Viking Therapeutic (VKTX) PT Lowered to $29 at Citi
-
H.C. Wainwright Keeps PT at $102 on Viking Therapeutic (VKTX), 'Varying Sentiments Flying Around, But We Are Happy
-
Stifel on Viking Therapeutic (VKTX) Sell-Off: 'an over-reaction to the successful Ph.2 VENTURE-Oral (13-week) outcome'
-
William Blair on Viking Therapeutic (VKTX) Sell-Off: 'extreme and unwarranted'
-
BTIG Reiterates Buy Rating on Viking Therapeutic (VKTX), PT $125
-
Truist Securities Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Novo Nordisk, Eli Lilly rise after Viking obesity trial data
-
JPMorgan on Viking Therapeutic (VKTX): 'we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile'
-
Mizuho: Viking (VKTX) Oral Obesity Program is 'Quite Discouraging'
-
Piper Sandler on Viking Therapeutic (VKTX): 'Strong Odds of Re-Rating of Oral VK2735 Sales'
-
Oppenheimer Reiterates Outperform Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) call put ratio 5.3 calls to 1 put with a focus on November 45 calls
-
Stifel Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Viking Therapeutic (VKTX)
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) Misses Q2 EPS by 13c
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
BTIG Reiterates Buy Rating on Viking Therapeutic (VKTX)

